351 related articles for article (PubMed ID: 35764956)
1. A study protocol of a randomized phase II trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma: the NeoRacing study.
Zhou M; Yang W; Xuan Y; Zou W; Wang Y; Zhang Z; Zhang J; Mo M; Zhou C; Liu Y; Zhang W; Zhang Z; He Y; Weng W; Tan C; Wang L; Huang D; Sheng W; Li H; Zhu H; Wang Y; Shen L; Zhang H; Wan J; Li G; Huang H; Wang Y; Zhang Z; Liu X; Xia F
BMC Cancer; 2022 Jun; 22(1):710. PubMed ID: 35764956
[TBL] [Abstract][Full Text] [Related]
2. Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Liu X; Jin J; Cai H; Huang H; Zhao G; Zhou Y; Wu J; Du C; Long Z; Fang Y; Ma M; Li G; Zhou M; Yin J; Zhu X; Zhu J; Sheng W; Huang D; Zhu H; Zhang Z; Lu Q; Xie L; Zhang Z; Wang Y
BMC Cancer; 2019 Jun; 19(1):606. PubMed ID: 31221115
[TBL] [Abstract][Full Text] [Related]
3. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
Lorenzen S; Biederstädt A; Ronellenfitsch U; Reißfelder C; Mönig S; Wenz F; Pauligk C; Walker M; Al-Batran SE; Haller B; Hofheinz RD
BMC Cancer; 2020 Sep; 20(1):886. PubMed ID: 32933498
[TBL] [Abstract][Full Text] [Related]
4. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B
BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674
[TBL] [Abstract][Full Text] [Related]
5. Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric cancer (GC) or gastro-oesophageal junction adenocarcinoma (GEJ): a multicentre, phase II, single-arm, open-label clinical trial (FRUTINEOGA) protocol.
Wu L; Yan H; Qin Y; Huang M; Wang T; Jin Q; Wei W
BMJ Open; 2024 Feb; 14(2):e075696. PubMed ID: 38341203
[TBL] [Abstract][Full Text] [Related]
6. Perioperative treatment and biomarker analysis of LP002, an anti-PD-L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer.
Tang JL; Zhang B; Xu JP; Qi L; Xin D; Wang L; Wang BZ; Tian YT; Li Y; Huang J
Cancer Med; 2023 Mar; 12(5):5639-5648. PubMed ID: 36341590
[TBL] [Abstract][Full Text] [Related]
7. Total neoadjuvant therapy for locally advanced gastric cancer and esophagogastric junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase II clinical trial.
Shi J; Li N; Tang Y; Jiang L; Yang L; Wang S; Song Y; Liu Y; Fang H; Lu N; Qi S; Chen B; Li Z; Liu S; Wang J; Wang W; Zhu S; Yang J; Li Y; Zhao D; Jin J
BMC Gastroenterol; 2022 Jul; 22(1):359. PubMed ID: 35902798
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma.
Sun W; Veeramachaneni N; Al-Rajabi R; Madan R; Kasi A; Al-Kasspooles M; Baranda J; Saeed A; Phadnis MA; Godwin AK; Olyaee M; Streeter N; Nagji A; Dai J; Williamson S
Cancer Med; 2023 Aug; 12(15):16098-16107. PubMed ID: 37326317
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (SHARED): Study Protocol of a Prospective, Multi-Center, Single-Arm Phase 2 Trial.
Wei J; Lu X; Liu Q; Fu Y; Liu S; Li L; Liu F; Fan X; Yang J; Yang Y; Zhao Y; Guan W; Liu B
Cancer Manag Res; 2022; 14():2007-2015. PubMed ID: 35747712
[TBL] [Abstract][Full Text] [Related]
10. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).
Leong T; Smithers BM; Michael M; Gebski V; Boussioutas A; Miller D; Simes J; Zalcberg J; Haustermans K; Lordick F; Schuhmacher C; Swallow C; Darling G; Wong R
BMC Cancer; 2015 Jul; 15():532. PubMed ID: 26194186
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.
Jiang H; Yu X; Li N; Kong M; Ma Z; Zhou D; Wang W; Wang H; Wang H; He K; Li Z; Lu Y; Zhang J; Zhao K; Zhang Y; Xu N; Li Z; Liu Y; Wang Y; Wang Y; Teng L
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296556
[TBL] [Abstract][Full Text] [Related]
12. Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial.
Jiang Z; Xie Y; Zhang W; Du C; Zhong Y; Zhu Y; Jiang L; Dou L; Shao K; Sun Y; Xue Q; Tian Y; Gao S; Zhao D; Zhou A
Gastric Cancer; 2024 May; 27(3):571-579. PubMed ID: 38457083
[TBL] [Abstract][Full Text] [Related]
13. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant SOX chemotherapy versus concurrent chemoradiotherapy after D2 radical resection of locally advanced esophagogastric junction (EGJ) adenocarcinoma: study protocol for a randomized phase III trial (ARTEG).
Shen J; Zhu X; Du Y; Zhu Y; Yu P; Yang L; Xu Z; Huang L; Zhang Y; Zhang Y; Liu L; Cheng X
Trials; 2021 Oct; 22(1):753. PubMed ID: 34717717
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma.
Manji GA; Lee S; Del Portillo A; May M; Ana SS; Alouani E; Sender N; Negri T; Gautier K; Ge L; Fan W; Xie M; Sethi A; Schrope B; Tan AC; Park H; Oberstein PE; Shah MA; Raufi AG
JAMA Oncol; 2023 Dec; 9(12):1702-1707. PubMed ID: 37856106
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial.
Jiang H; Zheng Y; Qian J; Mao C; Xu X; Li N; Xiao C; Wang H; Teng L; Zhou H; Wang S; Zhu D; Peng B; Shen L; Xu N
BMC Cancer; 2020 Aug; 20(1):760. PubMed ID: 32795349
[TBL] [Abstract][Full Text] [Related]
17. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
[TBL] [Abstract][Full Text] [Related]
18. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI.
Al-Batran SE; Goetze TO; Mueller DW; Vogel A; Winkler M; Lorenzen S; Novotny A; Pauligk C; Homann N; Jungbluth T; Reissfelder C; Caca K; Retter S; Horndasch E; Gumpp J; Bolling C; Fuchs KH; Blau W; Padberg W; Pohl M; Wunsch A; Michl P; Mannes F; Schwarzbach M; Schmalenberg H; Hohaus M; Scholz C; Benckert C; Knorrenschild JR; Kanngießer V; Zander T; Alakus H; Hofheinz RD; Roedel C; Shah MA; Sasako M; Lorenz D; Izbicki J; Bechstein WO; Lang H; Moenig SP
BMC Cancer; 2017 Dec; 17(1):893. PubMed ID: 29282088
[TBL] [Abstract][Full Text] [Related]
19. The CARDIA-trial protocol: a multinational, prospective, randomized, clinical trial comparing transthoracic esophagectomy with transhiatal extended gastrectomy in adenocarcinoma of the gastroesophageal junction (GEJ) type II.
Leers JM; Knepper L; van der Veen A; Schröder W; Fuchs H; Schiller P; Hellmich M; Zettelmeyer U; Brosens LAA; Quaas A; Ruurda JP; van Hillegersberg R; Bruns CJ
BMC Cancer; 2020 Aug; 20(1):781. PubMed ID: 32819399
[TBL] [Abstract][Full Text] [Related]
20. Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study).
Tokunaga M; Machida N; Mizusawa J; Ito S; Yabusaki H; Hirao M; Watanabe M; Imamura H; Kinoshita T; Yasuda T; Hihara J; Fukuda H; Yoshikawa T; Boku N; Terashima M
Gastric Cancer; 2024 May; 27(3):580-589. PubMed ID: 38243037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
